FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912478727> ?p ?o ?g. }

• W2912478727 endingPage "717" @default.
• W2912478727 startingPage "717" @default.
• W2912478727 abstract "Abstract Background: Patients with acute myeloid leukemia (AML) face poor outcomes and treatments with significant and debilitating toxicities. New regimens with improved efficacy and an improved side effect profile are needed. Documenting patient experience can assist in identifying unmet needs and in fostering drug development. We sought to understand the experience of patients with AML by prioritizing their AML-related worries as part of a larger patient-focused drug development initiative led by The Leukemia & Lymphoma Society. Methods: A robust community-centered approach was used to engage diverse expert and community stakeholders in the development of an instrument to prioritize patient worry. A pilot study was completed to refine the instrument which resulted in 13 patient-centered worries encompassing decision-making, treatment delivery, physical side effects, and psychosocial effects. To capture best-worst (BW) scores, patients were presented with repeated choice tasks prompting them to choose the attributes that they were most and least worried about among repeated subsets of attributes chosen using a balanced-incomplete block design. Results were analyzed using a conditional logistic regression with patients' choices of attributes as the dependent variable. A national survey of patients and caregivers was conducted with the instrument. Results were then compared with Likert ratings of the attributes for validation. Sub-group analysis compared patients currently in remission to those not in remission. Additional qualitative worries were also collected. Results: The survey was delivered to 5,353 potential participants. A total of 892 patients with AML participated; 832 completed all choice tasks. Patients were predominantly white (88%), married or partnered (72%), college-educated (66%), and privately-insured (79%). Many were currently employed (46%) while some were disabled (25%) or retired (22%). Most patients received an allogeneic stem cell transplant (64%) and the large majority (95%) were currently in remission. The mean time from diagnosis was 8 years (range = 1 - 40), and the mean age was 55 years (range = 19 - 87). Patients were most worried about the possibility of dying from AML (Regression result = 1.25, Standard Error (SE) = 0.030), followed by long-term side effects of treatments (Regression result = 1.05, SE = 0.030), being a burden to others (Regression result = 0.32, SE 0.029), and returning to daily activities (Regression result = 0.31, SE 0.028). Patients were least worried about communicating openly with doctors (Regression result = -1.25, SE 0.030), having access to the best medical care (Regression result = -0.75, SE 0.029) and having enough information about AML (Regression result = -0.62, SE 0.028). BW scores were highly correlated with Likert ratings (Spearman's rho = 0.93). Patients who were not in remission worried more about knowing about all the treatment options than coping with the emotional demands of AML, short-term side effects of treatments, the overall financial cost of AML, and choosing a treatment in a short amount of time. Overall, patients found it easy to understand the questions (78%), easy to answer all the questions (64%) and answered the questions consistently with their experience (89%). Conclusions: Identifying and prioritizing the worries of patients with AML are necessary to understand the experience of those affected by the disease. In this large, national sample representing mostly AML survivors, patients had the strongest worries about long-term clinical outcomes including the possibility of dying from their disease and the long-term side effects of therapy. Psychosocial effects were also worrisome including concerns about burdening others, returning to work, emotionally coping with AML, and the cost of treatment. Items related to treatment delivery and decision-making were less prioritized, perhaps illustrating the sufficient expertise and counseling from care providers. Patients who were not in remission were more concerned about understanding treatment options. Representing the largest study to date of the concerns of patients with AML, these data can serve to inform patient care and the development of new treatment options. Figure. Figure. Disclosures O'Donoghue: The Leukemia & Lymphoma Society: Employment. Bridges:The Leukemia & Lymphoma Society: Research Funding." @default.
• W2912478727 created "2019-02-21" @default.
• W2912478727 creator A5048770889 @default.
• W2912478727 creator A5050087636 @default.
• W2912478727 creator A5072733056 @default.
• W2912478727 creator A5073818028 @default.
• W2912478727 creator A5080444441 @default.
• W2912478727 creator A5090971178 @default.
• W2912478727 date "2018-11-29" @default.
• W2912478727 modified "2023-09-27" @default.
• W2912478727 title "Patients with AML Worry about More Than Just Dying: Quantifying Patient Experience Using Best-Worst Scaling" @default.
• W2912478727 doi "https://doi.org/10.1182/blood-2018-99-116669" @default.
• W2912478727 hasPublicationYear "2018" @default.
• W2912478727 type Work @default.
• W2912478727 sameAs 2912478727 @default.
• W2912478727 citedByCount "0" @default.
• W2912478727 crossrefType "journal-article" @default.
• W2912478727 hasAuthorship W2912478727A5048770889 @default.
• W2912478727 hasAuthorship W2912478727A5050087636 @default.
• W2912478727 hasAuthorship W2912478727A5072733056 @default.
• W2912478727 hasAuthorship W2912478727A5073818028 @default.
• W2912478727 hasAuthorship W2912478727A5080444441 @default.
• W2912478727 hasAuthorship W2912478727A5090971178 @default.
• W2912478727 hasConcept C105776082 @default.
• W2912478727 hasConcept C118552586 @default.
• W2912478727 hasConcept C126322002 @default.
• W2912478727 hasConcept C138496976 @default.
• W2912478727 hasConcept C150966472 @default.
• W2912478727 hasConcept C151956035 @default.
• W2912478727 hasConcept C15744967 @default.
• W2912478727 hasConcept C160735492 @default.
• W2912478727 hasConcept C162324750 @default.
• W2912478727 hasConcept C2777896191 @default.
• W2912478727 hasConcept C2779978724 @default.
• W2912478727 hasConcept C50522688 @default.
• W2912478727 hasConcept C512399662 @default.
• W2912478727 hasConcept C558461103 @default.
• W2912478727 hasConcept C71924100 @default.
• W2912478727 hasConceptScore W2912478727C105776082 @default.
• W2912478727 hasConceptScore W2912478727C118552586 @default.
• W2912478727 hasConceptScore W2912478727C126322002 @default.
• W2912478727 hasConceptScore W2912478727C138496976 @default.
• W2912478727 hasConceptScore W2912478727C150966472 @default.
• W2912478727 hasConceptScore W2912478727C151956035 @default.
• W2912478727 hasConceptScore W2912478727C15744967 @default.
• W2912478727 hasConceptScore W2912478727C160735492 @default.
• W2912478727 hasConceptScore W2912478727C162324750 @default.
• W2912478727 hasConceptScore W2912478727C2777896191 @default.
• W2912478727 hasConceptScore W2912478727C2779978724 @default.
• W2912478727 hasConceptScore W2912478727C50522688 @default.
• W2912478727 hasConceptScore W2912478727C512399662 @default.
• W2912478727 hasConceptScore W2912478727C558461103 @default.
• W2912478727 hasConceptScore W2912478727C71924100 @default.
• W2912478727 hasIssue "Supplement 1" @default.
• W2912478727 hasLocation W29124787271 @default.
• W2912478727 hasOpenAccess W2912478727 @default.
• W2912478727 hasPrimaryLocation W29124787271 @default.
• W2912478727 hasRelatedWork W1982423144 @default.
• W2912478727 hasRelatedWork W1983659550 @default.
• W2912478727 hasRelatedWork W1994083464 @default.
• W2912478727 hasRelatedWork W2049032002 @default.
• W2912478727 hasRelatedWork W2090940332 @default.
• W2912478727 hasRelatedWork W2401061489 @default.
• W2912478727 hasRelatedWork W2590742116 @default.
• W2912478727 hasRelatedWork W2982885904 @default.
• W2912478727 hasRelatedWork W3157297814 @default.
• W2912478727 hasRelatedWork W3214034395 @default.
• W2912478727 hasVolume "132" @default.
• W2912478727 isParatext "false" @default.
• W2912478727 isRetracted "false" @default.
• W2912478727 magId "2912478727" @default.
• W2912478727 workType "article" @default.